1. Home
  2. CISS vs SHPH Comparison

CISS vs SHPH Comparison

Compare CISS & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C3is Inc.

CISS

C3is Inc.

HOLD

Current Price

$0.86

Market Cap

1.7M

ML Signal

HOLD

Logo Shuttle Pharmaceuticals Holdings Inc.

SHPH

Shuttle Pharmaceuticals Holdings Inc.

BUY

Current Price

$4.01

Market Cap

2.1M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
CISS
SHPH
Founded
2022
2012
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7M
2.1M
IPO Year
2022
2022

Fundamental Metrics

Financial Performance
Metric
CISS
SHPH
Price
$0.86
$4.01
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 596.1K
20.7K
Earning Date
11-17-2026
09-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.82
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$0.38
52 Week High
$6.06
$6.15

Technical Indicators

Market Signals
Indicator
CISS
SHPH
Relative Strength Index (RSI) 35.91 58.72
Support Level $0.76 $3.21
Resistance Level $0.88 $4.34
Average True Range (ATR) 0.15 0.34
MACD -0.05 0.06
Stochastic Oscillator 8.39 88.80

Price Performance

Historical Comparison
CISS
SHPH

About CISS C3is Inc.

C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including national and private industrial users, commodity producers, and traders. The company owns and operates a fleet of two dry bulk carriers that transport bulk commodities such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.

About SHPH Shuttle Pharmaceuticals Holdings Inc.

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.

Share on Social Networks: